Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOREST-HCM Long-Term Open-Label Aficamten Treatment in Hypertrophic Cardiomyopathy
jRCT2051260092Recruiting
- Sponsor
- Cytokinetics
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by Cytokinetics. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on jRCT2051260092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260092.